EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 170 filers reported holding EAGLE PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is 0.73 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $334,000 | -60.3% | 4,813 | -69.5% | 0.00% | – |
| Q4 2017 | $842,000 | -59.9% | 15,767 | -55.3% | 0.00% | – |
| Q3 2017 | $2,102,000 | -24.4% | 35,245 | 0.0% | 0.00% | -100.0% |
| Q2 2017 | $2,780,000 | +584.7% | 35,245 | +619.7% | 0.00% | – |
| Q1 2017 | $406,000 | -46.4% | 4,897 | -73.8% | 0.00% | – |
| Q1 2016 | $757,000 | -72.1% | 18,700 | -38.9% | 0.00% | -100.0% |
| Q4 2015 | $2,715,000 | +39.7% | 30,617 | +16.6% | 0.00% | 0.0% |
| Q3 2015 | $1,943,000 | +352.9% | 26,250 | +395.3% | 0.00% | – |
| Q2 2015 | $429,000 | – | 5,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |